10x GenomicsTXG +1.79%62 PB Ratio is 5.58 as of Jun. 25, 2026, which is 21% below its 10-year median of 7.04. GuruFocus rates TXG with a GF Score™ of 62/100 and a GF Value™ of $19.00 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 611 Healthcare Providers & Services companies, 10x Genomics ranks worse than 83.31% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-25), 10x Genomics's share price is $35.22. 10x Genomics's Book Value per Share for the quarter that ended in Mar. 2026 was $6.31. Hence, 10x Genomics's PB Ratio of today is 5.58.
Warning Sign:
10x Genomics Inc stock PB Ratio (=5.48) is close to 2-year high of 5.51.
The historical rank and industry rank for 10x Genomics's PB Ratio or its related term are showing as below:
TXG'
s PB Ratio Range Over the Past 10 Years
Min: 1.3 Med: 7.04 Max: 366.67
Current: 5.58
During the past 9 years, 10x Genomics's highest PB Ratio was 366.67. The lowest was 1.30. And the median was 7.04.
TXG's PB Ratio is ranked worse than 83.31% of 611
companies
in the Healthcare Providers & Services industry
Industry Median: 1.98
vs TXG: 5.58
During the past 12 months, 10x Genomics's average Book Value Per Share Growth Rate was 10.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -3.80% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -3.50% per year.
During the past 9 years, the highest 3-Year average Book Value Per Share Growth Rate of 10x Genomics was 17.00% per year. The lowest was -7.20% per year. And the median was -3.40% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
10x Genomics PB Ratio Related Terms
10x Genomics PB Ratio Historical Data
* Premium members only.
The historical data trend for 10x Genomics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, 10x Genomics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
10x Genomics PB Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, 10x Genomics's PB Ratio distribution charts can be found below:
* The bar in red indicates where 10x Genomics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
10x Genomics's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
10x Genomics (TXG) has a PB Ratio of 5.58 as of Jun. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on 10x Genomics and its competitors. This is 21% below median its historical median of 7.04. Over the past decade, 10x Genomics' PB Ratio has ranged from 1.30 to 366.67. According to the industry distribution chart, 10x Genomics ranks #509 out of 611 companies in the Healthcare Providers & Services industry, placing it in the top 83.3%.
Is 10x Genomics' PB Ratio too high?
10x Genomics' current PB Ratio of 5.58 is 21% below median its 10-year median of 7.04. Over the past 10 years, this metric has ranged from a low of 1.30 to a high of 366.67. The Healthcare Providers & Services industry median PB Ratio is 1.98. 10x Genomics' value of 5.58 is 181.8% above this industry median. Based on the distribution chart, 10x Genomics ranks #509 out of 611 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, 10x Genomics has a GF Score™ of 62/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does 10x Genomics' PB Ratio compare to WAY and DOCS?
According to the Healthcare Providers & Services industry distribution chart, 10x Genomics ranks #509 out of 611 companies for PB Ratio. This places 10x Genomics in the lower half of its industry. The industry median PB Ratio is 1.98. 10x Genomics' value of 5.58 is 181.8% above this benchmark. Historically, 10x Genomics' own PB Ratio has ranged from 1.30 to 366.67 over the past decade. While the company's 10-year median is 7.04 vs. the industry median of 1.98, 10x Genomics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Healthcare Providers & Services company?
The median PB Ratio among Healthcare Providers & Services companies is 1.98, based on 611 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. 10x Genomics's current PB Ratio of 5.58 is 181.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on 10x Genomics and its competitors. For the Healthcare Providers & Services industry, the median PB Ratio is 1.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 10x Genomics's current PB Ratio is 5.58, which is 21% below median its own 10-year median of 7.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 10x Genomics stock overvalued right now?
Based on GuruFocus' analysis, 10x Genomics (TXG) is currently considered Significantly Overvalued. The stock's GF Value™ is $19.00, compared to a current price of $35.22 — trading 85.4% above its estimated fair value. The current PB Ratio is 5.58, which is 21% below median its 10-year median of 7.04 and 181.8% above the Healthcare Providers & Services industry median of 1.98. 10x Genomics' overall GF Score™ is 62/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For 10x Genomics (TXG), the current PB Ratio is 5.58 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 10x Genomics (TXG) Overvalued in 2026?
Based on GuruFocus' analysis, 10x Genomics stock appears to be overvalued.
The current stock price of $35.22 is trading 85.4% above its estimated GF Value™ of $19.00.
GuruFocus considers 10x Genomics to be Significantly Overvalued.
Key valuation signals for TXG:
PB Ratio: 5.58 (21% below median its 10-year median of 7.04)
GF Value™: $19.00 vs. price of $35.22 (85.4% above fair value)
Industry Position: 181.8% above the Healthcare Providers & Services median (#509 of 611)
No single metric tells the full story. See the TXG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
62GF Score
Get the complete analysis for TXG
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TXG has been successfully added to your 
